التفاصيل البيبلوغرافية
| العنوان: |
Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm |
| المؤلفون: |
Francesco Calvanese, Timothée Jacquesson, Romain Manet, Alexandre Vasiljevic, Hélène Lasolle, Francois Ducray, Gerald Raverot, Emmanuel Jouanneau |
| المصدر: |
Frontiers in Endocrinology, Vol 13 (2022) |
| بيانات النشر: |
Frontiers Media S.A., 2022. |
| سنة النشر: |
2022 |
| المجموعة: |
LCC:Diseases of the endocrine glands. Clinical endocrinology |
| مصطلحات موضوعية: |
papillary craniopharyngiomas, tumor biopsy, V600E BRAF mutation, B-RAF and MEK inhibitor targeted therapy, neoadjuvant treatment, Diseases of the endocrine glands. Clinical endocrinology, RC648-665 |
| الوصف: |
BackgroundSurgical and clinical management of craniopharyngiomas is associated with high long-term morbidity especially in the case of hypothalamic involvement. Improvements in knowledge of craniopharyngioma molecular biology may offer the possibility of safe and effective medical neoadjuvant treatments in a subset of patients harboring papillary subtype tumors with a BRAFV600E mutation.MethodWe report herein two cases of tubero-infundibular and ventricular Papillary Craniopharyngiomas in which BRAF/MEK inhibitor combined therapy was used as adjuvant (Case 1) or neoadjuvant (Case 2) treatment, with a 90% reduction in tumor volume observed after only 5 months. In Case 2 the only surgical procedure used was a minimal invasive biopsy by the trans-ventricular neuroendoscopic approach. As a consequence, targeted therapy was administered in purely neoadjuvant fashion. After shrinkage of the tumor, both patients underwent fractionated radiotherapy on the small tumor remnant to achieve long-term tumor control. A review of a previously reported case has also been performed.ResultThis approach led to tumor control with minimal long-term morbidity in both cases. No side effects or complications were reported after medical treatment and adjuvant radiotherapy.ConclusionOur experience and a review of the literature argue for a change in the current treatment paradigm for Craniopharyngiomas (CPs). In giant and invasive tumors, confirmation of BRAFV600E mutated PCPs by biopsy and BRAF/MEK inhibitor therapy before proposing other treatments may be useful to improve long term outcomes for patients. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
1664-2392 |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fendo.2022.882381/full; https://doaj.org/toc/1664-2392 |
| DOI: |
10.3389/fendo.2022.882381 |
| URL الوصول: |
https://doaj.org/article/3ad4eae4f70d408e9f2c298d6dc36ee7 |
| رقم الانضمام: |
edsdoj.3ad4eae4f70d408e9f2c298d6dc36ee7 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder